Journal of Experimental & Clinical Cancer Research 2025

6 papers
The 2025 edition of the Journal of Experimental & Clinical Cancer Research focused on precision oncology, specifically targeting drug delivery systems and the mechanisms of ferroptosis in overcoming treatment resistance. Research directions emphasized the use of active surface targeting for theranostic platforms and the study of subclonal resistance within heterogeneous tumors. Notable studies explored the long-term biological fate of engineered nanomaterials and the integration of multimodal data for personalized clinical risk stratification. Key publications investigated molecular regulators such as the FASN-USP5-GPX4 axis in breast cancer and the synergistic effects of EGFR inhibition with NAT10 inhibitors in colorectal cancer. The year also saw a trend toward applying artificial intelligence to clinical challenges, including predicting postoperative pathology from preoperative data and generalizing medical AI across diverse populations. Diagnostic advancements were highlighted by the development of liquid biopsy transcriptomic panels for gastric cancer risk assessment and the identification of regulatory circuits like ATG4B and SESN3 in T cell leukemogenesis. Prolific contributors included researchers such as Diwei Zheng, Ke Sun, and Linxue Zhang.

Top Research Directions

The 26 research directions with Journal of Experimental & Clinical Cancer Research 2025 papers, ranked by paper count, next to 2024. Share is the fraction of the edition’s papers in the direction.

#Direction20252024Share 2025Share 20242024 rank
1Bidirectional Functional Validation of Gene Expression in Disease Models1016.7%0.0%—
2Cross-Cancer Generalizability of Tumor Regulatory Pathways1016.7%0.0%—
3Cross-Platform Validation of Computational Biomarkers1016.7%0.0%—
4Deorphanizing E3 Ubiquitin Ligases and Their Substrates1116.7%16.7%4
5Engineering Precision Vehicles for Targeted RNA Delivery1016.7%0.0%—
6Harmonizing Multi-Site Data Pipelines to Mitigate Batch Effects1016.7%0.0%—
7Integrating Diagnostic Imaging and Targeted Therapy1016.7%0.0%—
8Integrating Heterogeneous Multi-Omics Data Layers1016.7%0.0%—
9Iterative Consensus Building with the Delphi Method1016.7%0.0%—
10Ligand Mediated Active Targeting of Nanocarriers1016.7%0.0%—
11Long-Term Clearance and Bioaccumulation of Therapeutic Nanomaterials1016.7%0.0%—
12Mathematical Frameworks for Quantifying Drug Synergy1016.7%0.0%—
13Mechanisms for Cross Disciplinary Knowledge Transfer1016.7%0.0%—
14Mechanisms of Synergy in Combination Cancer Therapies1016.7%0.0%—
15Multimodal Integration for Clinical Risk Stratification1116.7%16.7%11
16Predicting Rare Events under Extreme Class Imbalance1016.7%0.0%—
17Predictive Modeling with Public Cancer Genomics Data1016.7%0.0%—
18Preoperative Staging Inaccuracy and Stage Migration1016.7%0.0%—
19Quantifying Gene Expression with Real-Time PCR1016.7%0.0%—
20Resolving Intratumoral Heterogeneity for Precision Cancer Stratification1016.7%0.0%—
21Screening for Selective Cytotoxicity to Optimize Therapeutic Windows1016.7%0.0%—
22Substrate Recognition and Wiring in Targeted Proteasomal Degradation1116.7%16.7%19
23Temperature Responsive Matrices for Controlled Payload Delivery1016.7%0.0%—
24The Molecular Mechanics of Iron Dependent Cell Death1016.7%0.0%—
25Validating Physical Protein Interactions via Co-Immunoprecipitation1016.7%0.0%—

Download all directions as CSV

Institutions

Institutions credited by Journal of Experimental & Clinical Cancer Research 2025 papers: a paper credits every institution named in its affiliations, once. 41 institutions share 6 credited papers.

#InstitutionPapersShare20242024 rank
1051jg5p78 233.3%0—
200ca2c886 116.7%0—
300raa0r66 116.7%0—
400rg70c39 116.7%0—
501fmc2233 116.7%0—
6027nwsc63 116.7%0—
7028pgd321 116.7%0—
802afm7029 116.7%0—
9035af0m16 116.7%0—
1004hya7017 116.7%0—
1104mgfev69 116.7%0—
1205pb5hm55 116.7%0—
13Aarhus University 116.7%0—
14Aarhus University Hospital 116.7%0—
15Barts Cancer Institute 116.7%0—
16Centre National de la Recherche Scientifique 116.7%0—
17Christian Doppler Laboratory for Thermoelectricity 116.7%0—
18Essen University Hospital 116.7%0—
19Ghent University 116.7%0—
20Hebei Medical University 116.7%14
21Heinrich Heine University Düsseldorf 116.7%0—
22Institut Curie 116.7%0—
23Institut de Recherche pour le Développement 116.7%0—
24Jiangnan University 116.7%0—
25Medical University of Graz 116.7%0—
26Nanjing Medical University 116.7%0—
27Nantong University 116.7%0—
28National and Kapodistrian University of Athens 116.7%0—
29NHS England 116.7%0—
30Queen Mary University of London 116.7%0—

Download all institutions as CSV

About this data

Papers. Journal of Experimental & Clinical Cancer Research 2025 lists 6 papers on Lacuna, duplicate versions counted once; rejected and withdrawn submissions are left out.

Directions. Directions are Lacuna’s clustering of the concept elements extracted from each paper, so a paper can belong to several and direction counts add up to more than the paper count. A direction’s share is its papers divided by the edition’s papers. Comparisons with 2024 use shares, since the edition went from 6 to 6 papers.

Institutions. A paper credits each institution named in its affiliations, resolved to a ROR record, once. 6 of 6 papers (100.0%) credit at least one institution and are the base for institution shares; the rest have no resolved affiliation yet.

Data. Counts come from Lacuna’s data build of 2026-11-19 and change as papers are added. Tables as CSV: directions · institutions. Cite as: Lacuna, “Journal of Experimental & Clinical Cancer Research 2025”, https://lacuna.tiptreesystems.com/venue/journal-of-experimental-clinical-cancer-research/2025.

Top Authors

AuthorPapers
An Hendrix1
Ariane Hallermayr1
Gennaro Ciliberto1
Jean‐Yves Pierga1
Jennifer A. Fairley1
Patrizio Giacomini1
Vincent D. de Jager1
Zandra C. Deans1

Papers

Title
A novel regulatory circuit of ATG4B and SESN3 promotes T cell leukemogenesis
EGFR inhibition augments the therapeutic efficacy of the NAT10 inhibitor Remodelin in Colorectal cancer
FASN inhibits ferroptosis in breast cancer via USP5 palmitoylation-dependent regulation of GPX4 deubiquitination
Fostering the implementation of liquid biopsy in clinical practice: meeting report 2024 of the European Liquid Biopsy Society (ELBS)
Preoperative liquid biopsy transcriptomic panel for risk assessment of lymph node metastasis in T1 gastric cancer
PSMA-targeted theranostic nanoplatform achieves spatiotemporally precise therapy and triggers ferroptosis in prostate cancer treatment